申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0417560A1
公开(公告)日:1991-03-20
The present invention relates to certain 5-substituted pyrimidine nucleosides of formula (I) and pharmaceutically acceptable derivatives thereof and their use in the treatment of varicella zoster virus, cytomegalovirus and Epstein Barr virus infections. Also provided are pharmaceutical formulations and processes for the preparation of the compounds according to the invention.
wherein X represents an ethynylene group; R¹ represents an oxo or imino group; R² represents hydrogen, or a C₁₋₂ alkyl or a C₃₋₄ branched or cycloalkyl group; R³ represents a hydrogen atom or an acyl group optionally substituted by one or more halogen, alkyl, hydroxy or alkoxy substituents; and R⁴ represents a hydrogen atom or a hydroxy group; providing that (a) when R¹ is imino, R³ is hydrogen and R⁴ is hydrogen or hydroxy, R² does not represent a hydrogen atom, and (b) when R¹ is oxo; R³ is hydrogen and R⁴ is hydrogen or hydroxy, R² does not represent hydrogen, methyl, ethyl or isopropyl; or a pharmaceutically acceptable derivative thereof.
本发明涉及某些式(I)的 5-取代嘧啶核苷及其药学上可接受的衍生物,以及它们在治疗水痘带状疱疹病毒、巨细胞病毒和 Epstein Barr 病毒感染中的用途。此外,还提供了根据本发明制备化合物的药物制剂和工艺。
其中 X 代表乙炔基;R¹ 代表氧代或亚氨基;R² 代表氢,或 C₁₋₂烷基或 C₃₋₄ 支链或环烷基;R³ 代表氢原子或任选被一个或多个卤素、烷基、羟基或烷氧基取代基取代的酰基;R⁴ 代表氢原子或羟基;条件是:(a) 当 R¹ 为亚氨基,R³ 为氢,R⁴ 为氢或羟基时,R² 不代表氢原子;(b) 当 R¹ 为氧代,R³ 为氢,R⁴ 为氢或羟基时,R² 不代表氢、甲基、乙基或异丙基;或其药学上可接受的衍生物。